Celgene Quickly Reaches High Valuation Target
Celgene Corporation is a global biopharmaceutical company that develops and commercializes therapies for cancer and immune-inflammatory related diseases. Its products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. It also licenses FOCALIN XR and RITALIN.
[PostStockWidget stock_valuation="" pricetype="live" manual_date="Dec. 21, 2012, 2:04pm GMT" symbolcodes="'CELG'" symbolprices="88" div_align="right"]
On March 24, we bought a half position in this stock at $70.89 (post-split). The target has been reached at $88.
New Purple Chips Valuation Range: Low $71.00, High $88.00
HIGH VALUATION IN CELGENE AT $USD 87.98 (CELG, $87.93) HALF POSITION
This trade paid no dividends and delivered a TOTAL RETURN: +24.1%
